Document is current
Any future updates will be listed below
-
Authors
Ardeshir, Amir https://orcid.org/0000-0002-4330-4659
O’Hagan, Daniel
Mehta, Isha https://orcid.org/0000-0002-6009-0787
Shandilya, Siddhartha https://orcid.org/0000-0002-9179-5878
Hopkins, Lincoln L. J. https://orcid.org/0000-0002-3874-3585
Adamson, Lourdes
Kuroda, Marcelo J.
Hahn, Patricia A. https://orcid.org/0000-0002-4338-4660
da Costa, Lucas A. B.
Fuchs, Sebastian P.
Martinez-Navio, Jose M. https://orcid.org/0000-0003-0560-5407
Gardner, Matthew R. https://orcid.org/0000-0003-2872-7597
Van Rompay, Koen K. A. https://orcid.org/0000-0002-7375-1337
Magnani, Diogo M. https://orcid.org/0000-0002-1773-2406
Lifson, Jeffrey D.
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Farzan, Michael https://orcid.org/0000-0002-2990-5319
Desrosiers, Ronald C.
Das, Jishnu https://orcid.org/0000-0002-5747-064X
Martins, Mauricio A. https://orcid.org/0000-0001-8336-216X
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 27 June 2025
First Online: 30 July 2025
Competing interests
: M.A.M., M.R.G. and M.F. have significant financial interests in Emmune Inc., a company that is developing HIV immunotherapies based on the immunoadhesin eCD4-Ig. These potential conflicts of interest are being managed by the authors’ respective institutions. The other authors declare no competing interests.
